Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jan 1;13(1):50-57.
doi: 10.1093/ecco-jcc/jjy125.

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Brian G Feagan  1 , William J Sandborn  2 , Jean-Frédéric Colombel  3 , Sharon O' Byrne  4 , Javaria M Khalid  5 , Christian Kempf  4 , Parnia Geransar  4 , Fatima Bhayat  6 , David T Rubin  7
Affiliations
Clinical Trial

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Brian G Feagan et al. J Crohns Colitis. .

Abstract

Background and aims: Extraintestinal manifestations [EIMs] such as arthritis/arthralgia are common in inflammatory bowel disease. We performed post hoc analyses of data from the GEMINI studies to evaluate the effect of vedolizumab, a gut-selective anti-trafficking agent, on arthritis/arthralgia.

Methods: Sustained resolution of baseline arthritis/arthralgia, worsening of baseline arthritis/arthralgia, the occurrence of new arthritis/arthralgia, and the composite of new/worsening arthritis/arthralgia were evaluated. Cox modelling was used for time-to-event analysis. The influence of corticosteroid-tapering was also investigated.

Results: In Crohn's disease [CD] patients, vedolizumab was significantly less likely than placebo to be associated with new/worsening arthritis/arthralgia (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.44-0.89). Similar incidences of sustained resolution of arthritis/arthralgia occurred with vedolizumab and placebo. In CD patients on corticosteroids at baseline, a decrease in corticosteroid dose increased the risk of new/worsening arthritis/arthralgia (odds ratio [OR], 7.49; 95% CI, 3.50-15.97) regardless of treatment; and in those achieving corticosteroid-free status, arthritis/arthralgia was less likely with vedolizumab than with placebo [HR, 0.14; 95% CI, 0.05-0.35]. In ulcerative colitis [UC] patients, vedolizumab and placebo showed a similar incidence of new/worsening of arthritis/arthralgia. In UC patients on corticosteroid at baseline, arthritis/arthralgia was more likely in those achieving corticosteroid-free status than in those continuing corticosteroids (HR 2.63 [95% CI 1.13-6.11]); and in those achieving corticosteroid-free status, the incidence of arthritis/arthralgia was similar with vedolizumab and placebo.

Conclusions: Vedolizumab therapy was associated with a reduced likelihood of new/worsening arthritis/arthralgia in CD and no increased incidence of these events in UC.

Studies included [clincialtrials.gov, number]: GEMINI 1 [NCT00783718]; GEMINI 2 [NCT00783692]; GEMINI 3 [NCT01224171].

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier analyses for [A] time to sustained resolution of baseline arthritis/arthralgia in CD [GEMINI 2], [B and C] time to occurrence of new arthritis/arthralgia in CD [GEMINI 2 and 3 respectively], [D] time to new/worsening arthritis/arthralgia in CD [GEMINI 2], and [E] time to new/worsening of arthritis/arthralgia in UC [GEMINI 1]. In GEMINI 1 and 2, the VDZ group includes both induction responders and non-responders, the VDZ/PLA group is responders only, and the PLA group is both responders and non-responders. CD, Crohn’s disease; PLA, placebo; VDZ, vedolizumab; UC, ulcerative colitis.
See this image and copyright information in PMC

References

    1. Zippi M, Corrado C, Pica R, et al. . Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol 2014;20:17463–7. - PMC - PubMed
    1. Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013;10:585–95. - PubMed
    1. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome?World J Gastroenterol 2011;17:2702–7. - PMC - PubMed
    1. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982–92. - PMC - PubMed
    1. Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med 2011;4:123–31. - PMC - PubMed

Publication types

MeSH terms

Associated data